Eric Danielson Email & Phone Number

Cambridge, Massachusetts, United States

• Led in vivo and ex vivo assay development for target validation and PK/PD assessment in CMT2A and ALS mouse models.
• Designed and executed phenotypic screens for cell-based assays(primary cultured neurons and mouse embryonic fibroblasts).
• Supervised and trained junior team members to perform image-based assays as well as mouse behavioral evaluation.
• Pioneered the lab infrastructure as the first bench scientist, establishing vendor relationships, sourcing equipment, and developing lab operation protocols, fueling the company's early growth.
• Authored IACUC animal protocols to meet all regulatory requirements and promote ethical animal research.

• Supervised and trained three junior scientists, fostering their skill development and contributing to a collaborative research environment.
• Conducted phenotypic screening using a novel patient-derived iPSC co-culture assay to assess lead compounds' efficacy in promoting ALS phenotype survival and rescue.
• Spearheaded the development and deployment of a single deep learning-based pipeline that quantified images across multiple imaging platforms. (Operetta, Incucyte, Cytation5, Cx7).
• Established a new in vivo translational team, securing equipment, training personnel, and developing operational protocols to evaluate lead compounds in a 3k synucleinopathy Parkinson's mouse model.

• Performed high content RNAi screening of autism/schizophrenia rare-variant genes using 13-channel multiplexed imaging, identifying convergent changes in the molecular network of synapses.
• Applied 13-channel multiplexed imaging to rat hippocampal neurons, revealing diverse synapse classes and distinct synapsin 1 regulation in excitatory/inhibitory synapses.
• Collaborated effectively in a cross-functional team to integrate automated workflows for highthroughput imaging and data analysis, accelerating research progress.

Worcester, Massachusetts

• Designed innovative phenotypic screens to identify therapeutic pathways for ALS in primary cultured rodent cortical neuronal cultures.
• Generated and characterized a new ALS mouse model that develops neurodegeneration prior to protein aggregation accumulation, offering new insights for mechanistic and therapeutic studies.
• Discovered disruption of the actin cytoskeleton with ALS mutant proteins is linked to nuclear transport dysfunction, proposing actin targeting as a new therapeutic strategy for ALS.

Medical College Of Wisconsin

• Employed a combination of electrophysiology and confocal microscopy to evaluate the functional consequences of mutations in scaffolding proteins on synaptic signaling in primary neurons and organotypic slices.
• Characterized the function of S-SCAM at synapses, revealing its impact on synaptic transmission and revealing a potential mechanism for its role in early-onset schizophrenia.
• Developed SynPAnal, an open-source software tool for the rapid quantification of synaptic puncta from fluorescence microscopy images, facilitating efficient data analysis.

Madison, Wisconsin Area

• Maintained knockout mouse colony: performed animal husbandry, genotyping, oral dosing, plasma collection, tissue harvesting, tissue processing and analysis.
• Characterized extra-renal production of vitamin D using a beta-galactose reporter gene in CYP27B1 null mice.
• Examined the role calbindin D9k in vitamin D regulated intestinal calcium absorption.

Doctor Of Philosophy (Phd), Molecular And Cellular Neurobiology

Ba, Biology And Computerscience

Activities and Societies: fencing

Education record